Protection from malaria infection using liver-targeted siRNA

Area of Science:

• Hepatology
• Immunology
• Infectious Diseases

Background:

• Malaria parasites infect the liver asymptomatically before causing disease.
• CD81 on hepatocytes is a key entry receptor for Plasmodium falciparum sporozoites.
• Exploiting CD81 for malaria prevention remains a challenge.

Purpose of the Study:

• To investigate the efficacy of CD81-targeted small interfering RNA (siRNA) for malaria prevention.
• To assess the ability of siRNA to silence CD81 expression in hepatocytes in vivo.
• To evaluate the impact of CD81 silencing on Plasmodium infection in a mouse model.

Main Methods:

• N-acetylgalactosamine (GalNAc)-conjugated siRNA targeting CD81 was administered to mice.
• CD81 expression in the liver was measured following siRNA administration.
• Mice were infected with malaria sporozoites to assess liver and blood stage infection.
• Human liver-chimeric mice were used to evaluate efficacy against human Plasmodium falciparum.

Main Results:

• CD81-targeted GalNAc-siRNA efficiently silenced CD81 expression in mouse and human hepatocytes in vivo.
• siRNA treatment blocked malaria parasite liver infection in a dose-dependent manner.
• Preventing liver infection with siRNA halted the onset of blood stage malaria.
• Reduced Plasmodium falciparum infection was observed in human liver-chimeric mice.

Conclusions:

• CD81-targeted siRNA represents a promising host-directed strategy for malaria prevention.
• RNA interference offers a clinically relevant approach to block parasite liver stage infection.
• This method effectively prevents malaria by targeting a critical host factor for parasite entry.